Volume 8, Issue 2 (2022)                   Pharm Biomed Res 2022, 8(2): 91-94 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Pashmforosh M, Shariati S, Aghaei Nezhad H, Haghighat M. Possible Benefits of Paclitaxel Therapy for COVID-19. Pharm Biomed Res. 2022; 8 (2) :91-94
URL: http://pbr.mazums.ac.ir/article-1-420-en.html
1- Department of Basic Sciences, Faculty of Medical Sciences, Behbahan University of Medical Sciences, Behbahan, Iran.
2- Department of Toxicology, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Abstract:   (1622 Views)
The coronavirus disease 2019 (COVID-19) was reported in Wuhan, China, in late December 2019 and soon became the most serious global health challenge due to the high rate of human-to-human transmission. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a single-stranded RNA virus and belongs to the large Coronaviridae family [1]. 
Full-Text [PDF 412 kb]   (767 Downloads) |   |   Full-Text (HTML)  (586 Views)  
Type of Study: Short Communication | Subject: Pharmacology

Add your comments about this article : Your username or Email:
CAPTCHA

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2022 CC BY-NC 4.0 | Pharmaceutical and Biomedical Research

Designed & Developed by : Yektaweb